Larimar Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Larimar Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 6.7% en 83.4% per jaar. De winst per aandeel zal naar verwachting groeien met 7.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -47.5% zijn.

Belangrijke informatie

6.7%

Groei van de winst

7.7%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	83.4%
Toekomstig rendement op eigen vermogen	-47.5%
Dekking van analisten	Good
Laatst bijgewerkt	21 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:ZA71 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	12	-145	-170	-119	9
12/31/2025	N/A	-102	-117	-95	10
12/31/2024	N/A	-73	-112	-91	9
9/30/2024	N/A	-65	-59	-58	N/A
6/30/2024	N/A	-58	-43	-43	N/A
3/31/2024	N/A	-45	-36	-36	N/A
12/31/2023	N/A	-37	-34	-33	N/A
9/30/2023	N/A	-33	-31	-31	N/A
6/30/2023	N/A	-33	-27	-27	N/A
3/31/2023	N/A	-33	-28	-28	N/A
12/31/2022	N/A	-35	-28	-28	N/A
9/30/2022	N/A	-35	-29	-29	N/A
6/30/2022	N/A	-44	-36	-35	N/A
3/31/2022	N/A	-47	-39	-38	N/A
12/31/2021	N/A	-51	-42	-42	N/A
9/30/2021	N/A	-56	-44	-44	N/A
6/30/2021	N/A	-49	-43	-43	N/A
3/31/2021	N/A	-48	-44	-44	N/A
12/31/2020	N/A	-42	-42	-42	N/A
9/30/2020	N/A	-34	-40	-40	N/A
6/30/2020	N/A	-33	-35	-35	N/A
3/31/2020	N/A	-25	-26	-26	N/A
12/31/2019	N/A	-23	-23	-23	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ZA71 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ZA71 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ZA71 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat ZA71 volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat ZA71 volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat ZA71 binnen 3 jaar verliesgevend zal zijn.

Larimar Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

New major risk - Revenue and earnings growth

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought €100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Independent Director recently bought €419k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

New 90-day low: €15.00

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

New 90-day high: €18.90

New 90-day high: €18.50

New 90-day high: €15.42

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high - €13.82

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven